NTRK2 and Parkinson disease: BDNF’s preferential receptor, tropomyosin kinase B receptor (TrkB), is widely distributed in the central nervous system, including dopaminergic neurons of the substantia nigra, and increasing BDNF and/or TrkB expression is considered beneficial in PD [54,55].